Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- AmpliMed Corporation
- Registration Number
- NCT00697060
- Locations
- πΊπΈ
USC Norris Cotton Cancer Center, Los Angeles, California, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈMary Crowley Research Center, Dallas, Texas, United States
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- Interventions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT00637247
- Locations
- πΊπΈ
Birmingham Hematology and Oncology- US Oncology, Birmingham, Alabama, United States
πΊπΈAZ Onc Associates D.B.A. Hematology Oncology- US Oncology, Tucson, Arizona, United States
πΊπΈArizona Clinical Research Center, Tucson, Arizona, United States
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
- Conditions
- Non-small Cell Lung CancerBreast CancerProstate Cancer
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT00327288
- Locations
- πΊπΈ
Investigational Site 008, Houston, Texas, United States
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Adenocarcinoma
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 105
- Registration Number
- NCT00327327
- Locations
- πΊπΈ
Arizona Clinical Research Center, Tucson, Arizona, United States
πΊπΈUS Oncology Orlando, Cancer Centers of FL, Ocoee, Florida, United States
πΊπΈUS Oncology Indiana, Indianapolis, Indiana, United States
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT00327600
- Locations
- πΊπΈ
Investigational Site 009, Los Angeles, California, United States
πΊπΈInvestigational Site 002, Santa Monica, California, United States
πΊπΈUniversity of CO Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Prev
- 1
- 2
- Next